Leerink Partnrs Has Negative Estimate for JANX Q3 Earnings

Key Points

• Analyst estimates for Janux Therapeutics have been lowered, with Q3 2025 EPS now projected at ($0.59), down from ($0.54).
• Raymond James Financial has initiated coverage on Janux Therapeutics with an "outperform" rating and a target price of $65.00.
• The stock has recently seen a 2.8% increase, with an average target price of $91.89 according to MarketBeat data.

Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - Leerink Partnrs dropped their Q3 2025 EPS estimates for Janux Therapeutics in a report released on Monday, August 11th. Leerink Partnrs analyst J. La. Rosa now anticipates that the company will post earnings per share of ($0.59) for the quarter, down from their prior forecast of ($0.54). The consensus estimate for Janux Therapeutics' current full-year earnings is ($1.38) per share. Leerink Partnrs also issued estimates for Janux Therapeutics' Q4 2025 earnings at ($1.22) EPS, FY2025 earnings at ($2.74) EPS, FY2026 earnings at ($5.50) EPS, FY2027 earnings at ($6.22) EPS, FY2028 earnings at ($4.88) EPS and FY2029 earnings at ($2.77) EPS.

A number of other research firms also recently weighed in on JANX. Piper Sandler initiated coverage on shares of Janux Therapeutics in a research note on Monday. They set an "overweight" rating and a $42.00 price target for the company. Raymond James Financial initiated coverage on shares of Janux Therapeutics in a research note on Friday, July 11th. They set an "outperform" rating and a $65.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $86.90.

Janux Therapeutics Trading Down 2.6%

Shares of Janux Therapeutics stock traded down $0.6760 during midday trading on Thursday, reaching $24.8540. The company had a trading volume of 298,302 shares, compared to its average volume of 940,047. The company has a market capitalization of $1.49 billion, a price-to-earnings ratio of -13.80 and a beta of 2.86. The stock has a fifty day simple moving average of $24.60 and a 200 day simple moving average of $28.08. Janux Therapeutics has a 1-year low of $21.97 and a 1-year high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.07).

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in JANX. LPL Financial LLC bought a new position in Janux Therapeutics during the fourth quarter worth about $439,000. Geode Capital Management LLC increased its position in shares of Janux Therapeutics by 7.9% during the fourth quarter. Geode Capital Management LLC now owns 714,956 shares of the company's stock worth $38,288,000 after acquiring an additional 52,362 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Janux Therapeutics by 52.9% during the fourth quarter. Wells Fargo & Company MN now owns 13,251 shares of the company's stock worth $709,000 after acquiring an additional 4,585 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Janux Therapeutics by 77.7% during the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock worth $54,000 after acquiring an additional 442 shares in the last quarter. Finally, Cerity Partners LLC bought a new stake in shares of Janux Therapeutics during the fourth quarter worth $239,000. 75.39% of the stock is currently owned by institutional investors.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.